These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 7909495)
1. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Press MF; Hung G; Godolphin W; Slamon DJ Cancer Res; 1994 May; 54(10):2771-7. PubMed ID: 7909495 [TBL] [Abstract][Full Text] [Related]
2. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689 [TBL] [Abstract][Full Text] [Related]
3. Quantitation of HER-2/neu oncoprotein overexpression in invasive breast cancer by image analysis: a study comparing fresh and paraffin-embedded material. van Diest PJ; Baak JP; Chin D; Theeuwes JW; Bacus SS Anal Cell Pathol; 1991 Jul; 3(4):195-202. PubMed ID: 1679345 [TBL] [Abstract][Full Text] [Related]
4. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. van de Vijver MJ; Peterse JL; Mooi WJ; Wisman P; Lomans J; Dalesio O; Nusse R N Engl J Med; 1988 Nov; 319(19):1239-45. PubMed ID: 2903446 [TBL] [Abstract][Full Text] [Related]
5. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Pauletti G; Godolphin W; Press MF; Slamon DJ Oncogene; 1996 Jul; 13(1):63-72. PubMed ID: 8700555 [TBL] [Abstract][Full Text] [Related]
6. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Ross JS; Fletcher JA Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Bigsby RM; Li AX; Bomalaski J; Stehman FB; Look KY; Sutton GP Obstet Gynecol; 1992 Jan; 79(1):95-100. PubMed ID: 1345772 [TBL] [Abstract][Full Text] [Related]
8. HER-2/neu oncogene expression and proliferation in breast cancers. Bacus SS; Ruby SG; Weinberg DS; Chin D; Ortiz R; Bacus JW Am J Pathol; 1990 Jul; 137(1):103-11. PubMed ID: 1973597 [TBL] [Abstract][Full Text] [Related]
9. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients. Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885 [TBL] [Abstract][Full Text] [Related]
10. Distribution and patterns of staining of Neu oncogene product in benign and malignant breast diseases. Hanna W; Kahn HJ; Andrulis I; Pawson T Mod Pathol; 1990 Jul; 3(4):455-61. PubMed ID: 1977159 [TBL] [Abstract][Full Text] [Related]
11. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. Bacus SS; Bacus JW; Slamon DJ; Press MF Arch Pathol Lab Med; 1990 Feb; 114(2):164-9. PubMed ID: 1967930 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma. Vang R; Cooley LD; Harrison WR; Reese T; Abrams J Am J Clin Pathol; 2000 May; 113(5):669-74. PubMed ID: 10800399 [TBL] [Abstract][Full Text] [Related]
13. The role of the HER-2/neu oncogene in gynecologic cancers. Cirisano FD; Karlan BY J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816 [TBL] [Abstract][Full Text] [Related]
14. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675 [TBL] [Abstract][Full Text] [Related]
15. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Gancberg D; Lespagnard L; Rouas G; Paesmans M; Piccart M; Di Leo A; Nogaret JM; Hertens D; Verhest A; Larsimont D Am J Clin Pathol; 2000 May; 113(5):675-82. PubMed ID: 10800400 [TBL] [Abstract][Full Text] [Related]
16. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors. Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149 [TBL] [Abstract][Full Text] [Related]
17. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Bacus SS; Stancovski I; Huberman E; Chin D; Hurwitz E; Mills GB; Ullrich A; Sela M; Yarden Y Cancer Res; 1992 May; 52(9):2580-9. PubMed ID: 1373672 [TBL] [Abstract][Full Text] [Related]
18. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605 [TBL] [Abstract][Full Text] [Related]
19. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Ross JS; Fletcher JA Am J Clin Pathol; 1999 Jul; 112(1 Suppl 1):S53-67. PubMed ID: 10396301 [TBL] [Abstract][Full Text] [Related]
20. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma. Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]